Associations - ALK rearrangement

BIOMARKER:

ALK rearrangement

Entrez ID:

238

Related biomarkers:

‹

›

ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib + bevacizumab Sensitive: C3 – Early Trials crizotinib + bevacizumab Sensitive : C3
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ALK rearrangement ALK rearrangement	Non-Hodgkin’s Lymphoma NHL	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
ALK rearrangement ALK rearrangement	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3
ALK rearrangement ALK rearrangement	Renal Cell Carcinoma RCC	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK rearrangement ALK rearrangement	Sarcoma Sarcoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	bevacizumab Sensitive: C4 – Case Studies bevacizumab Sensitive : C4
ALK rearrangement ALK rearrangement	Renal Cell Carcinoma RCC	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
ALK rearrangement ALK rearrangement	Lung Cancer Lung Cancer	BMS-722782 Sensitive: D – Preclinical BMS-722782 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES